World's Best Scientists 2026 revealed!
Award Badge
Medicine
Switzerland
2026

D-Index & Metrics

Medicine

D-Index
184
Citations
174726
World Ranking
311
National Ranking
2

Michael Weller publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Michael Weller sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 1,508 publications — 99th percentile

99% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Michael Weller D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Michael Weller sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 184 D-Index — 98th percentile

98% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • 2026 - Research.com Medicine in Switzerland Leader Award
  • 2025 - Research.com Medicine in Switzerland Leader Award
  • 2023 - Research.com Medicine in Switzerland Leader Award
  • 2022 - Research.com Medicine in Switzerland Leader Award

Overview

Michael Weller is affiliated with the University of Zurich in Switzerland and has a primary research focus in the field of Medicine. Their work spans several specialized subfields, including Genetics, Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging, Molecular Biology, and Oncology.

The scientist's research topics cover a broad spectrum of areas related to brain cancer and medical imaging. These topics include:

  • Glioma Diagnosis and Treatment
  • Brain Metastases and Treatment
  • Meningioma and schwannoma management
  • Radiomics and Machine Learning in Medical Imaging
  • Cancer Genomics and Diagnostics
  • Medical Imaging Techniques and Applications
  • Immunotherapy and Immune Responses

Weller has published extensively in prominent scientific venues. Frequent publication platforms for their work include:

  • Neuro-Oncology
  • Journal of Clinical Oncology
  • European Journal of Cancer
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Neuro-Oncology Advances

Among recent notable papers authored or co-authored by Michael Weller are:

  • EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood, 2020, Nature Reviews Clinical Oncology
  • Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma, 2020, JAMA Oncology
  • Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions, 2020, Neuro-Oncology
  • EANO guideline on the diagnosis and management of meningiomas, 2021, Neuro-Oncology
  • Single-Cell Mapping of Human Brain Cancer Reveals Tumor-Specific Instruction of Tissue-Invading Leukocytes, 2020, Cell

Weller collaborates frequently with several other researchers in the field. The most common co-authors include:

  • Martin J. van den Bent
  • Émilie Le Rhun
  • Matthias Preusser
  • Patrick Y. Wen
  • Patrick Roth

Best Publications

  • Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma

    Roger Stupp;Warren P. Mason;Martin J. van den Bent;Michael Weller

  • Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

    Roger Stupp;Monika E. Hegi;Warren P. Mason;Martin J. van den Bent

  • MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma

    Monika E Hegi;Annie-Claire Diserens;Thierry Gorlia;Marie-France Hamou

  • DNA methylation-based classification of central nervous system tumours

    David Capper;David Capper;David Capper;David T. W. Jones;Martin Sill;Volker Hovestadt

  • Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial

    Roger Stupp;Roger Stupp;Roger Stupp;Sophie Taillibert;Sophie Taillibert;Andrew Kanner;William Read;William Read

  • An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor

    Christiane A. Opitz;Ulrike M. Litzenburger;Ulrike M. Litzenburger;Felix Sahm;Martina Ott

  • Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.

    Christian Hartmann;Christian Hartmann;Jochen Meyer;Jörg Balss;David Capper

  • Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial

    Wolfgang Wick;Michael Platten;Christoph Meisner;Joerg Felsberg

  • EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood.

    Michael Weller;Martin van den Bent;Matthias Preusser;Emilie Le Rhun

  • Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial

    Roger Stupp;Roger Stupp;Monika E Hegi;Thierry Gorlia;Sara C Erridge

  • Current state of immunotherapy for glioblastoma

    Michael Lim;Yuanxuan Xia;Chetan Bettegowda;Michael Weller

  • Long-term survival with glioblastoma multiforme

    Dietmar Krex;Barbara Klink;Christian Hartmann;Andreas Von Deimling

  • Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: Implications for classification of gliomas

    Christian Hartmann;Christian Hartmann;Bettina Hentschel;Wolfgang Wick;Wolfgang Wick;David Capper

  • Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial

    David A. Reardon;Alba A. Brandes;Antonio Omuro;Paul Mulholland

  • Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo.

    Simone Fulda;Wolfgang Wick;Michael Weller;Klaus Michael Debatin;Klaus Michael Debatin

  • Correlation of O6-Methylguanine Methyltransferase (MGMT) Promoter Methylation With Clinical Outcomes in Glioblastoma and Clinical Strategies to Modulate MGMT Activity

    Monika E. Hegi;Lili Liu;James G. Herman;Roger Stupp

  • Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma

    Roger Stupp;Roger Stupp;Roger Stupp;Sophie Taillibert;Sophie Taillibert;Andrew Kanner;William Read;William Read

  • European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas

    Michael Weller;Martin van den Bent;Jörg C Tonn;Roger Stupp

  • NOA-04 Randomized Phase III Trial of Sequential Radiochemotherapy of Anaplastic Glioma With Procarbazine, Lomustine, and Vincristine or Temozolomide

    Wolfgang Wick;Christian Hartmann;Corinna Engel;Mandy Stoffels

  • Lomustine and Bevacizumab in Progressive Glioblastoma

    Wolfgang Wick;Thierry Gorlia;Martin Bendszus;Martin Taphoorn

Frequent Co-Authors

Wolfgang Wick
Wolfgang Wick German Cancer Research Center
Guido Reifenberger
Guido Reifenberger Heinrich Heine University Düsseldorf
Andreas von Deimling
Andreas von Deimling Heidelberg University
Roger Stupp
Roger Stupp Northwestern University
Martin J. van den Bent
Martin J. van den Bent Erasmus University Rotterdam
Johannes Dichgans
Johannes Dichgans University of Tübingen
Felix Sahm
Felix Sahm University Hospital Heidelberg
Manfred Westphal
Manfred Westphal Universität Hamburg
Stefan M. Pfister
Stefan M. Pfister German Cancer Research Center
David Capper
David Capper Charité - University Medicine Berlin

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you're exploring a career in medicine but want more flexible or alternative options, there are several online degree pathways that offer excellent opportunities. For those already in the nursing field, earning an online phd nursing can open doors to advanced research, teaching, and leadership roles. This is ideal for professionals seeking the highest level of nursing education without sacrificing their current commitments.

Students or working nurses looking to advance more affordably might consider enrolling in cheap rn to bsn online programs to increase their career prospects and earning potential. Even if your background isn't in nursing, you can transition with direct entry msn programs for non-nursing majors, which provide a fast-track bridge into the profession for bachelor’s degree holders from other disciplines.

For those concerned about admission barriers, some schools offer an easiest bsn program to get into, making the healthcare field more accessible than ever. By considering these related online programs, you can find flexible ways to pursue a rewarding healthcare career without following the traditional medical degree path.

Best Scientists Citing Michael Weller

Trending Scientists

Recently Published Articles